BSC
RGC icon

BOLTON SECURITIES CORPORATION’s Regencell Bioscience RGC Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,000
Closed -$567K – 2106
2025
Q4 		$567K Hold
27,000
– – 0.03% 504
2025
Q3 		$417K Buy
+27,000
New +$387K 0.02% 558

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marex Group
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
GSA Capital Partners
GSA Capital Partners London, United Kingdom $1.59B AUM 39.8% 1-Year Est. Return
Vident Advisory
Vident Advisory Alpharetta, Georgia $13.9B AUM 53.47% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's RGC Position: Q1 2026 in Review

BOLTON SECURITIES CORPORATION sold out of Regencell Bioscience (RGC) in Q1 2026, closing a stake of 27,000 shares — an estimated $567K sold.

BOLTON SECURITIES CORPORATION first reported a position in RGC in Q3 2025 and held it in 2 quarters. The position peaked at $567K in Q4 2025. 33 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • BOLTON SECURITIES CORPORATION reported no remaining Regencell Bioscience position as of Q1 2026 after selling out during the quarter.
  • BOLTON SECURITIES CORPORATION sold 27,000 Regencell Bioscience shares in Q1 2026, an estimated $567K.
  • BOLTON SECURITIES CORPORATION first reported a position in Regencell Bioscience in Q3 2025 and held it in 2 quarters.
  • BOLTON SECURITIES CORPORATION's Regencell Bioscience position peaked at $567K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q1 2026, filed 12 Nov 2026.